Cargando…

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab

Rheumatoid arthritis (RA) is a chronic systemic autoimmune condition which affects approximately 1% of the adult population worldwide and is characterized by joint inflammation, with extra-articular features being common. Interleukin 6 (IL-6) is one of the chief pro-inflammatory cytokines found in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negoescu, Andra F., Östör, Andrew J. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883250/ https://www.ncbi.nlm.nih.gov/pubmed/27747493 http://dx.doi.org/10.1007/s40744-014-0007-2

Ejemplares similares

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
por: Besada, Emilio
Publicado: (2014)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
por: Nakashima, Yasuharu, et al.
Publicado: (2014)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
por: Malaviya, Anshuman P, et al.
Publicado: (2012)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
por: Wang, Geng, et al.
Publicado: (2015)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
por: Yilmaz, Sedat, et al.
Publicado: (2013)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
por: Al-Shakarchi, Israa, et al.
Publicado: (2013)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis
por: Jones, Graeme, et al.
Publicado: (2010)

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials
por: Moots, Robert J., et al.
Publicado: (2017)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
por: Chiu, Yee, et al.
Publicado: (2012)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Benefits of Exercise in Rheumatoid Arthritis
por: Cooney, Jennifer K., et al.
Publicado: (2011)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
por: Ostor, Andrew J., et al.
Publicado: (2021)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
por: Bykerk, Vivian P, et al.
Publicado: (2012)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
por: Ahn, Soo Min, et al.
Publicado: (2022)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Applying refinement to the use of mice and rats in rheumatoid arthritis research
por: Hawkins, Penny, et al.
Publicado: (2015)

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis
por: Babkoor, Doaa, et al.
Publicado: (2022)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
por: Patel, Aarat M, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kipfd25ucnlq29uut4l3rq8q8g